208 related articles for article (PubMed ID: 34593007)
21. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
Adelaiye-Ogala R; Budka J; Damayanti NP; Arrington J; Ferris M; Hsu CC; Chintala S; Orillion A; Miles KM; Shen L; Elbanna M; Ciamporcero E; Arisa S; Pettazzoni P; Draetta GF; Seshadri M; Hancock B; Radovich M; Kota J; Buck M; Keilhack H; McCarthy BP; Persohn SA; Territo PR; Zang Y; Irudayaraj J; Tao WA; Hollenhorst P; Pili R
Cancer Res; 2017 Dec; 77(23):6651-6666. PubMed ID: 28978636
[TBL] [Abstract][Full Text] [Related]
22. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 acts as a protein kinase to regulate glioblastoma progression by activating the AKT/forkhead box O1 pathway.
Zhao K; Yu C; Luo J; Huang M; Wen Q; Zhao N
Acta Biochim Pol; 2022 Feb; 69(1):165-172. PubMed ID: 35143148
[TBL] [Abstract][Full Text] [Related]
23. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
[TBL] [Abstract][Full Text] [Related]
24. TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma.
Guo X; Li R; Bai Q; Jiang S; Wang H
J Cell Mol Med; 2020 Dec; 24(24):14441-14452. PubMed ID: 33145941
[TBL] [Abstract][Full Text] [Related]
25. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
[No Abstract] [Full Text] [Related]
26. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Yan L; Ding B; Liu H; Zhang Y; Zeng J; Hu J; Yao W; Yu G; An R; Chen Z; Ye Z; Xing J; Xiao K; Wu L; Xu H
Theranostics; 2019; 9(26):8377-8391. PubMed ID: 31754403
[TBL] [Abstract][Full Text] [Related]
27. Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth.
Chesney J; Clark J; Klarer AC; Imbert-Fernandez Y; Lane AN; Telang S
Oncotarget; 2014 Aug; 5(16):6670-86. PubMed ID: 25115398
[TBL] [Abstract][Full Text] [Related]
28. PFKFB4 Promotes Breast Cancer Metastasis via Induction of Hyaluronan Production in a p38-Dependent Manner.
Gao R; Liu Y; Li D; Xun J; Zhou W; Wang P; Liu C; Li X; Shen W; Su W; Qiao H; Stupack DG; Luo N
Cell Physiol Biochem; 2018; 50(6):2108-2123. PubMed ID: 30415245
[TBL] [Abstract][Full Text] [Related]
29. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
[TBL] [Abstract][Full Text] [Related]
30. Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification.
Lu Z; Pan Y; Wang S; Wu J; Miao C; Wang Z
Eur J Med Res; 2024 Apr; 29(1):236. PubMed ID: 38622715
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.
Huang D; Ding Y; Zhou M; Rini BI; Petillo D; Qian CN; Kahnoski R; Futreal PA; Furge KA; Teh BT
Cancer Res; 2010 Feb; 70(3):1063-71. PubMed ID: 20103651
[TBL] [Abstract][Full Text] [Related]
32. Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways.
Xie Y; Shangguan W; Chen Z; Zheng Z; Chen Y; Zhong Q; Zhang Y; Yang J; Zhu D; Xie W
Drug Des Devel Ther; 2021; 15():5061-5074. PubMed ID: 34938069
[TBL] [Abstract][Full Text] [Related]
33. G6PD upregulates Cyclin E1 and MMP9 to promote clear cell renal cell carcinoma progression.
Zhang Q; Ni Y; Wang S; Agbana YL; Han Q; Liu W; Bai H; Yi Z; Yi X; Zhu Y; Sai B; Yang L; Shi Q; Kuang Y; Yang Z; Zhu Y
Int J Med Sci; 2022; 19(1):47-64. PubMed ID: 34975298
[No Abstract] [Full Text] [Related]
34. SOX6 represses tumor growth of clear cell renal cell carcinoma by HMG domain-dependent regulation of Wnt/β-catenin signaling.
Chen L; Xie Y; Ma X; Zhang Y; Li X; Zhang F; Gao Y; Fan Y; Gu L; Wang L; Zhang X; Fu B
Mol Carcinog; 2020 Oct; 59(10):1159-1173. PubMed ID: 32794610
[TBL] [Abstract][Full Text] [Related]
35. Deficiency of the X-inactivation escaping gene
Zheng Q; Li P; Zhou X; Qiang Y; Fan J; Lin Y; Chen Y; Guo J; Wang F; Xue H; Xiong J; Li F
Theranostics; 2021; 11(18):8674-8691. PubMed ID: 34522206
[No Abstract] [Full Text] [Related]
36. PON1 hypermethylation is associated with progression of renal cell carcinoma.
Li X; Yu Q
J Cell Mol Med; 2019 Oct; 23(10):6646-6657. PubMed ID: 31400051
[TBL] [Abstract][Full Text] [Related]
37. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
38. CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma.
Sekino Y; Takemoto K; Murata D; Babasaki T; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Taniyama D; Shigeta M; Kuraoka K; Mita K; Kaneko M; Sentani K; Oue N; Teishima J
Anticancer Res; 2021 Oct; 41(10):4875-4883. PubMed ID: 34593435
[TBL] [Abstract][Full Text] [Related]
39. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of ALPK2 blocks development and progression of renal cell carcinoma.
Jiang J; Han P; Qian J; Zhang S; Wang S; Cao Q; Shao P
Exp Cell Res; 2020 Jul; 392(2):112029. PubMed ID: 32330508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]